DCB-USA LLC and the Development Center for Biotechnology have patented heterocycle compounds acting as fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of cancer, acute respiratory distress syndrome, asthma, arthritis, chronic obstructive pulmonary disease, lung injury, ischemia-reperfusion injury and septicemia.
Forx Therapeutics AG has discovered new bicyclo heteroaryl poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Idorsia Pharmaceuticals Ltd. has patented macrocyclic compounds acting as orexin OX2 receptor agonists reported to be useful for the treatment of obesity, pain, fatigue, inflammation, cognitive, sleep, eating and mood disorders.
Work at Genecode AS has led to the identification of sulfonamide or sulfone compounds acting as GFRα1-RET receptor complex activators potentially useful for the treatment of neurological disorders.
Hanmi Pharmaceutical Co Ltd. has synthesized new heterobicyclic compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors and reported to be useful for the treatment of cancer.
Semmelweis University and University of Debrecen have jointly identified isochroman compounds reported to be useful for the treatment of bacterial infections.
Work at Ensem Therapeutics Inc. has led to the discovery of anilino-pyrazole derivatives acting as cannabinoid CB2 receptor agonists. As such, they are reported to be useful for the treatment of anxiety disorders, autoimmune disease, depression, neurodegeneration, neuroinflammation, osteoarthritis, chronic pain and substance abuse and dependence, among others.
Compounds acting as histone acetyltransferase KAT6A (MOZ; MYST-3) and KAT7 (HBO-1; MYST-2) inhibitors are reported in an Ideaya Biosciences Inc. patent as potentially useful for the treatment of cancer.
Deciphera Pharmaceuticals LLC has described new dual serine/threonine-protein kinase B-Raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) and microtubule destabilizers (tubulin polymerization inhibitors) potentially useful for the treatment of cancer.
RSS